As the first and only company to deliver a successful Phase 3 study with a myostatin inhibitor, Scholar Rock is building a robust pipeline of anti-myostatin product candidates to serve patients by addressing a broad range of rare, severe, and debilitating neuromuscular diseases. The 2026 strategy centers on securing U.S. and European regulatory approvals and commercial launch for apitegromab in children and adults with SMA, expanding development of apitegromab into infants under two years of age and FSHD, and advancing its broader anti-myostatin pipeline including subcutaneous apitegromab and SRK-439.
Cyborg Score Rationale
The company reflects very weak current fundamentals (no revenue, large losses, and heavy cash burn) partially offset by constructive technical momentum and a mixed-but-manageable near-term outlook with cash runway into 2027 and strong trial results, tempered by FDA/third-party manufacturing compliance delays. Clinical validation is strong but commercialization execution risk remains substantial.
Top Insights
Primary objective is bringing apitegromab to market, with a supplemental BLA (sBLA) expected to be submitted later in 2026 with a second manufacturing site.
The company has an estimated $365 million in cash, cash equivalents and marketable securities as of December 31, 2025, providing runway into 2027.
Phase 2 FORGE trial for facioscapulohumeral muscular dystrophy (FSHD) is on track to initiate in mid-2026, expanding addressable market beyond SMA.
SRK-439, a novel subcutaneously administered myostatin inhibitor, has dosing underway in Phase 1 healthy volunteers with topline data expected in H2 2026.
Named Competitors
TBK1 inhibitors — Precision medicines for serious diseases
CAR-T immunotherapy — Gene-edited cell therapies
Immunotherapy pipeline — Cell-based and gene therapies
Recent Developments
(January 2026) Company provided 2026 strategic update highlighting transformative year ahead with focus on regulatory approvals and commercial launch for apitegromab
(November 2025) Completed constructive Type A meeting with FDA following receipt of Complete Response Letter, advancing pathway toward BLA resubmission
(March 2025) Achieved significant regulatory milestones in U.S. and European regulatory activities for apitegromab
Open the full interactive Scholar Rock Holding Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.